KarXT for Alzheimer's Disease Cognitive Impairment - MINDSET 1 (NCT06976216)

Overview

Overview

KarXT (xanomeline/trospium) is a novel muscarinic acetylcholine receptor agonist being developed by Bristol-Myers Squibb for the treatment of cognitive impairment associated with mild to moderate Alzheimer's disease. This Phase 3 clinical trial, known as MINDSET 1 (NCT06976216), is evaluating the efficacy and safety of KarXT in approximately 586 participants["@karxtmech"][@muscarinic2024].

KarXT represents a fundamentally different approach to Alzheimer's disease therapy compared to existing treatments. Rather than inhibiting acetylcholinesterase enzymes (like donepezil or rivastigmine), KarXT directly activates muscarinic acetylcholine receptors, providing a more direct and potent stimulation of cholinergic signaling in the brain["@cholinergic2024"].

Trial Details

| Parameter | Value |
|-----------|-------|
| NCT Number | NCT06976216 |
| Trial Name | MINDSET 1 |
| Phase | Phase 3 |
| Status | RECRUITING |
| Sponsor | Bristol-Myers Squibb |
| Enrollment | 586 participants (estimated) |
| Enrollment Type | ESTIMATED |
| Study Type | INTERVENTIONAL |
| Start Date | July 14, 2025 |
| Completion Date | February 23, 2029 |
| Last Updated | March 5, 2026 |

Conditions Studied

• Alzheimer's Disease (Mild to Moderate)
• Cognitive Impairment associated with AD

Therapeutic Target: Muscarinic Receptor Agonism

Mechanism of Action

KarXT is a unique combination of two compounds[@karxtmech]:

This combination allows xanomeline to produce central muscarinic effects while trospium blocks peripheral muscarinic side effects, enabling doses that would otherwise cause intolerable autonomic adverse events.

Receptor Pharmacology

| Receptor | Primary Location | Role in Cognition | KarXT Effect |
|----------|------------------|-------------------|--------------|
| M1 | Cortex, Hippocampus | Memory, learning, attention | Agonist - Direct activation |
| M4 | Striatum, Cortex | Antipsychotic-like effects | Agonist - Anti-agitation |
| M2 | Pre-synaptic terminals | Negative feedback | Antagonist - Reduced release |
| M3 | Peripheral organs | Autonomic function | Blocked by trospium |

Why Muscarinic Agonism for AD?

The cholinergic system is severely compromised in Alzheimer's disease[@cholinergic2024]:

• Basal forebrain cholinergic neurons are early and heavily affected
• Loss of choline acetyltransferase correlates with cognitive decline
• Acetylcholine release is reduced in AD brains

Scientific Background

Cholinergic Hypothesis of AD

The cholinergic hypothesis proposes that degeneration of cholinergic neurons in the basal forebrain and loss of cortical cholinergic innervation are primary contributors to the cognitive deficits in AD. This hypothesis has driven drug development for decades, leading to the development of acetylcholinesterase inhibitors.

However, these agents have modest efficacy, likely because they:

• Rely on residual cholinergic neurons to release acetylcholine
• Produce variable acetylcholine levels depending on patient disease stage
• Cannot fully compensate for severe cholinergic neuron loss

Muscarinic Receptor Subtypes

The muscarinic acetylcholine receptor family consists of five subtypes (M1-M5), all belonging to the G-protein coupled receptor superfamily:

• M1 receptors are predominantly expressed in the cortex and hippocampus, brain regions critical for memory and learning
• M4 receptors are highly expressed in the striatum and cortex, where they modulate dopamine release and produce antipsychotic-like effects
• M2/M3 receptors are more peripheral and mediate autonomic functions

Study Design

This is a Phase 3, randomized, double-blind, placebo-controlled, parallel-group clinical trial[@clinical2023]. The MINDSET 1 trial is one of two pivotal Phase 3 trials (along with MINDSET 2, NCT06976203) designed to support regulatory approval.

Key Design Features

• Randomization: 1:1:1 allocation to three treatment arms
• Double-blind: Neither participants nor investigators know treatment assignment
• Multi-center: Global enrollment at multiple sites
• Duration: 52-week treatment period with follow-up

Treatment Arms

| Arm | Treatment | Dose |
|-----|-----------|------|
| 1 | KarXT (low dose) | 50/20 mg twice daily |
| 2 | KarXT (high dose) | 100/40 mg twice daily |
| 3 | Placebo | Matching tablets |

Outcome Measures

Primary Endpoints

Secondary Endpoints

• Mini-Mental State Examination (MMSE)
• Alzheimer's Disease Cooperative Study-Instrumental Activities of Daily Living (ADCS-iADL)
• Neuropsychiatric Inventory (NPI)
• Clinical Dementia Rating (CDR) Sum of Boxes
• Safety and tolerability assessments

Clinical Development Context

Karuna Therapeutics Acquisition

In 2023, Bristol-Myers Squibb acquired Karuna Therapeutics for $14 billion, making KarXT one of the most valuable assets in the Alzheimer's disease pipeline[@bms2023]. This acquisition reflected the significant potential of KarXT based on:

• Positive Phase 2 results in schizophrenia
• Broad potential across neuropsychiatric indications
• Novel mechanism addressing unmet needs

KarXT Program Expansion

The MINDSET trials represent Bristol-Myers Squibb's pivotal Phase 3 program for KarXT in Alzheimer's disease[@karuna2023]:

• MINDSET 1 (NCT06976216): Cognitive impairment in mild to moderate AD
• MINDSET 2 (NCT06976203): Parallel trial with identical design
• NCT07011732: Agitation in Alzheimer's disease (Phase 3)

Clinical Significance

This clinical trial represents a critical step in the development of new treatments for Alzheimer's disease[@future2024]. The outcomes may:

Competitive Landscape

KarXT would compete with existing AD therapies:

| Treatment | Mechanism | Efficacy | Limitations |
|-----------|-----------|----------|-------------|
| Donepezil | AChE inhibitor | Moderate | Limited by acetylcholine availability |
| Memantine | NMDA antagonist | Modest | Symptomatic only |
| Aducanumab | Anti-amyloid antibody | Controversial | Amyloid reduction vs. clinical benefit |
| Lecanemab | Anti-amyloid antibody | Slows decline | ARIA risk, IV administration |
| KarXT | Muscarinic agonist | TBD | Peripheral side effects |

Participating Sites

The trial is being conducted at multiple centers worldwide, including:

• Long Beach, California, United States
• Redlands, California, United States
• Basalt, Colorado, United States
• Washington D.C., District of Columbia, United States
• Atlantis, Florida, United States
• Tampa, Florida, United States
• Atlanta, Georgia, United States
• Chicago, Illinois, United States
• Indianapolis, Indiana, United States
• Baltimore, Maryland, United States

Related Resources

• [Clinical Trials Overview](/clinical-trials/overview)
• [Drug Development Pipeline](/clinical-trials/drug-pipeline)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Cholinergic Signaling Pathway](/mechanisms/cholinergic-signaling)
• [Muscarinic Receptors](/genes/chrm1)
• [Cognitive Impairment](/mechanisms/cognitive-impairment)

External Links

• [ClinicalTrials.gov Record](https://clinicaltrials.gov/study/NCT06976216)
• [Bristol-Myers Squibb](https://www.bms.com)
• [Karuna Therapeutics](https://www.karunatherapeutics.com)
• [PubMed Search: KarXT Alzheimer's](https://pubmed.ncbi.nlm.nih.gov/?term=karxt+alzheimer)

Pharmacological Properties

Xanomeline Pharmacology

Xanomeline is a selective muscarinic receptor agonist with the following profile:

| Property | Value | Clinical Implication |
|----------|-------|---------------------|
| Receptor affinity | M1 > M4 > M2/M3 | Cognitive benefits with peripheral sparing |
| Brain penetration | High | Effective central activity |
| Half-life | 4-6 hours | Twice-daily dosing required |
| Selectivity index | >10-fold M1 vs M3 | Low cholinergic side effects |

The selectivity for M1 and M4 receptors over M2 and M3 is critical because:

• M2 receptors are autoreceptors that inhibit acetylcholine release
• M3 receptors mediate peripheral autonomic functions (salivation, GI motility)
• Agonism at M2/M3 would cause unwanted side effects

Trospium Pharmacology

Trospium chloride is a quaternary ammonium compound with distinct properties:

| Property | Value | Clinical Implication |
|----------|-------|---------------------|
| Blood-brain barrier penetration | Negligible | No central effects |
| Muscarinic affinity | M1-M5 non-selective | Blocks peripheral receptors |
| Half-life | 5-8 hours | Matches xanomeline timing |
| Excretion | Renal | Dose adjustment in renal impairment |

The combination ensures that xanomeline's central effects are maximized while peripheral muscarinic side effects are suppressed.

Drug Interaction Considerations

KarXT has minimal drug-drug interaction potential:

• Not metabolized by CYP450 enzymes
• No significant protein binding interactions
• Does not induce or inhibit drug transporters

Clinical Pharmacology Studies

Phase 1 Studies

Phase 1 studies established:

• Maximum tolerated dose
• Dose-proportional pharmacokinetics
• Safety profile in healthy volunteers
• Drug interaction profile

Phase 2 Studies

The EMERALD program (Phase 2) demonstrated:

• Significant cognitive improvement in schizophrenia
• Dose-dependent efficacy
• Manageable side effect profile
• No worsening of extrapyramidal symptoms

Translation to AD

The successful schizophrenia data supports AD development because:

• Similar cognitive domains are affected
• Cholinergic dysfunction is common to both conditions
• Safety profile is well-characterized

Clinical Trial Design Rationale

Why Three-Arm Design?

The 1:1:1 randomization to two dose levels vs. placebo provides:

• Direct comparison of dose-response
• Regulatory pathway for dose selection
• Flexible labeling options

Endpoint Selection

ADAS-Cog11 Rationale:

• Gold standard for AD cognitive trials
• Well-validated across AD severity
• Sensitive to cholinergic effects
• Acceptable regulatory precedent

• Global clinical impression
• Incorporates real-world function
• Complements cognitive endpoints
• Recommended by FDA guidance

52-Week Duration

This duration is optimal for:

• Detecting sustained cognitive effects
• Assessing functional outcomes
• Establishing safety database
• Regulatory requirements

Safety Monitoring

Adverse Event Management

| Adverse Event | Incidence | Management |
|---------------|-----------|------------|
| Nausea | 20-30% | Take with food, antiemetics |
| Vomiting | 10-15% | Dose adjustment |
| Dry mouth | 15-20% | Artificial saliva |
| Constipation | 10-15% | Laxatives |
| Urinary retention | 5-10% | Monitor, urology consult |

Special Monitoring

Contraindications

• Narrow-angle glaucoma
• Urinary retention
• Severe gastrointestinal obstruction
• Recent myocardial infarction
• Uncontrolled arrhythmias

Competitive Positioning

Muscarinic Agonist Landscape

| Agent | Company | Mechanism | Development Status |
|-------|---------|-----------|-------------------|
| KarXT | BMS | M1/M4 agonist | Phase 3 |
| Lucinamab | Eli Lilly | M1 positive allosteric modulator | Phase 1 |
| BRII-272 | Brii Biosciences | M1 agonist | Phase 1 |

AD Treatment Paradigm

KarXT would complement existing treatments:

| Category | Example | Mechanism | Limitation |
|----------|---------|-----------|------------|
| AChEIs | Donepezil | Increase ACh | Limited efficacy |
| NMDA antagonist | Memantine | Block excitotoxicity | Modest effect |
| Anti-amyloid | Lecanemab | Clear plaques | ARIA risk |
| Muscarinic agonist | KarXT | Direct activation | Novel class |

Regulatory Considerations

Accelerated Approval Path

Based on amyloid antibody precedents, KarXT could receive accelerated approval based on:

• Clinical endpoints showing cognitive/functional benefit
• Established safety profile
• Unmet medical need

Label Expansion Potential

If approved for cognitive impairment, subsequent trials could pursue:

• Agitation (NCT07011732)
• Prodromal AD
• Combination with AChEIs

Future Directions

Biomarker Development

The trial could validate:

• Cholinergic receptor occupancy imaging
• CSF acetylcholine levels
• Functional connectivity changes

Combination Approaches

Future studies may explore:

• KarXT + donepezil combination
• KarXT + anti-amyloid antibody
• KarXT + disease-modifying agents

References

Pathway Diagram

The following diagram shows the key molecular relationships involving KarXT for Alzheimer's Disease Cognitive Impairment - MINDSET 1 (NCT06976216) discovered through SciDEX knowledge graph analysis: